What is the story behind concussion “postbiotic.”
By Rahul Jonty
Pro Football Talk ran a story this week that has the whole field talking: a gut molecule might reduce brain damage from concussions.
According to PFT — citing New Scientist — mice dosed with a certain molecule before a traumatic brain injury suffer less brain damage and perform better on cognitive tests. In humans, the researchers found higher natural levels of this molecule lead to less swelling around brain lesions and better neurological outcomes six months after injury.
The molecule is indole-3-propionic acid (IPA).
What is IPA?
IPA is a chemical found in the gut. After you eat tryptophan (say, a big turkey sandwich), then specific gut bacteria digest it into smaller pieces and individual molecules. IPA is one of those small molecules. Your cells can’t make it — it exists only if you’re carrying the right gut bugs (Clostridium sporogenes and related species). The molecule is known to be able to cross the blood–brain barrier, and its role as a free-radical scavenger.
So how is this chemical related to concussions? A concussion does two kinds of damage: the primary impact, and the resulting secondary cascade — swelling, inflammation, oxidative stress — that unfolds over the following hours and days. The resultant secondary cascade does a large share of the real harm which is where IPA comes in to dampen this effect.
Why this isn’t nonsense
Three things give this story support beyond a single mouse experiment.
The idea is almost 30 years old. Poeggeler et al. (Brain Research, 1999) established IPA as a potent hydroxyl radical scavenger in the brain. A companion paper in the Journal of Biological Chemistry that year found its scavenging capacity exceeded melatonin’s. At the time this way a surprising finding as melatonin was thought as the most potent natural scavenger. IPA was later investigated as an Alzheimer’s therapeutic under the trade name OXIGON. It never reached market.
Pre-treatment already worked once. In 2009 (Journal of Neuroscience Research), Mongolian gerbils were given oral IPA 15 days before inducing brain ischemia (stroke). Nearly 57% of vulnerable hippocampal neurons survived, with less markers of the secondary inflammatory cascade. That’s the whole prophylactic concept, demonstrated in a different injury model 17 years ago.
It keeps working. Stroke, blood–brain barrier protection, spinal cord injury, radiation damage, and Alzheimer’s models have all seen positive results with IPA studies repeating across models and labs. There’s even a patent (US 10,278,958) filed for using IPA levels as a risk factor for damages produced by head injury, naming “high intensity contact sports” in the claims. The football application isn’t a modern journalist’s leap. It’s been part of the commercial story for years.
The catch, and it’s a big one
No human being has ever been given IPA before a head impact under controlled conditions.
The first dedicated oral IPA trial in healthy adults (iPROACT-pilot, NCT06674018) is a safety study — determining what dose you can safely take. Not whether it works.
Neuroprotection science has a long graveyard of compounds that saved rodent brains and failed in humans. And IPA isn’t uncomplicated: in heart muscle cells, short-term exposure improved mitochondrial function while chronic exposure impaired it. Nobody knows what a season-long dose would do.
It’s also sold as a research chemical, not a regulated supplement. For an athlete, the real short-term risk isn’t IPA — it’s whatever else is in the unregulated bottle.
Is this the NFL deflecting?
Fair question. The honest answer: not this study — but notice the nuance.
Nothing connects this research to the NFL. IPA science is academic, spans nearly three decades, and most studies mention stroke and dementia. The story reached football through Mike Florio, hardly a league publicist.
But the shape of the story deserves scrutiny. “Players could take something protective” quietly moves the burden from the league — rules, practice limits, exposure reduction — onto the individual player’s supplement shelf. That feels like a familiar move, and the NFL has earned the suspicion. A 2016 House Energy and Commerce investigation concluded the league improperly tried to steer a federal injury research grant award away from a prominent Boston University critic. The NFL denied the allegations. It was the same year a league executive first conceded the football–CTE link at all.
So, with IPA, there’s no conspiracy to read into here. But if this finding starts appearing in league safety messaging before it appears in a human trial, that’s the tell.
Bottom line
A gut metabolite with decades of credentials, a real precedent for pre-injury protection, and a coherent mechanism aimed at the part of a concussion that actually does the lingering damage.
Let’s keep an eye on the data surrounding IPA; but for now, it’s just a mouse study, and it does not stop a single hit from landing.
Nothing here moves a 2026 return-to-play timeline or TIE Worry Score. File it under watch this, not act on this.
